Jessica Allegretti, MD, MPH, FACG

Brigham and Women’s Hospital, Harvard Medical School

Poster(s):

• P2580 - The Efficacy of Maintenance Treatment with Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results at Week 44 by Biologic/Janus Kinase History
  Monday, October 28, 2024

  10:30 AM – 4:00 PM ET

• P2581 - Guselkumab Binding to CD64+ IL-23–Producing Myeloid Cells Enhances Potency for Neutralizing IL-23 Signaling
  Monday, October 28, 2024

  10:30 AM – 4:00 PM ET